Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Third party research

Gabather: Redefining Cognitive Disorder Treatment - Analyst Group

Gabather

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Gabather AB (“Gabather” or “the Company”) is advancing GT-002, a first-in-class GABAA-modulator, through Phase II clinical trials, targeting cognitive dysfunction. With a fully funded schizophrenia Phase II trial and a planned expansion into Phase II addressing dementia, the Company addresses a multi-billion-dollar CNS market with high unmet medical need. Gabather’s differentiated mechanism of action, strong patent portfolio, broad indication potential and expanding research efforts positions the Company to drive long-term value creation. The Company is in discussions with potential partners, further strengthening Gabather’s commercial prospects. Analyst Group considers the ongoing rights issue a compelling opportunity with an attractive Risk/Reward profile at a Pre-Money valuation of SEK 713.2k.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.